Paragon 28, Inc.

NYSE FNA

Paragon 28, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -40.24 M

Paragon 28, Inc. Operating Cash Flow is USD -40.24 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 33.76% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Paragon 28, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -60.75 M, a -59.57% change year over year.
  • Paragon 28, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -38.07 M, a -1,063.34% change year over year.
  • Paragon 28, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 3.95 M.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
Loading...
NYSE: FNA

Paragon 28, Inc.

CEO Mr. Albert DaCosta
IPO Date Oct. 15, 2021
Location United States
Headquarters 14445 Grasslands Drive
Employees 574
Sector Consumer Discretionary
Industries
Description

Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Similar companies

VREX

Varex Imaging Corporation

USD 13.52

1.05%

GKOS

Glaukos Corporation

USD 147.95

-2.58%

OFIX

Orthofix Medical Inc.

USD 17.51

0.81%

NPCE

NeuroPace, Inc.

USD 11.84

-2.23%

SGHT

Sight Sciences, Inc.

USD 3.15

-2.78%

BRKR

Bruker Corporation

USD 61.26

-2.69%

CVRX

CVRx, Inc.

USD 16.15

7.38%

CNMD

CONMED Corporation

USD 67.79

-2.46%

LIVN

LivaNova PLC

USD 47.63

0.66%

IRMD

IRadimed Corporation

USD 57.52

1.79%

SIBN

SI-BONE, Inc.

USD 15.70

-3.27%

ITGR

Integer Holdings Corporation

USD 138.83

2.72%

KIDS

OrthoPediatrics Corp.

USD 23.55

-5.80%

LUNG

Pulmonx Corporation

USD 6.84

-2.98%

StockViz Staff

January 15, 2025

Any question? Send us an email